Orthofix International N.V. (OFIX) Updates FY17 Earnings Guidance
Orthofix International N.V. (NASDAQ:OFIX) issued an update on its FY17 earnings guidance on Monday morning. The company provided earnings per share guidance of $1.54-1.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.53. The company issued revenue guidance of $422-425 million, compared to the consensus revenue estimate of $414.14 million.
Orthofix International N.V. (NASDAQ OFIX) opened at 48.33 on Wednesday. Orthofix International N.V. has a 52-week low of $32.51 and a 52-week high of $49.60. The company’s market cap is $872.07 million. The company’s 50-day moving average price is $45.44 and its 200-day moving average price is $40.49.
Orthofix International N.V. (NASDAQ:OFIX) last posted its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The company had revenue of $108.90 million during the quarter, compared to analyst estimates of $102.94 million. Orthofix International N.V. had a return on equity of 10.04% and a net margin of 1.88%. Orthofix International N.V.’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.41 earnings per share. Equities research analysts expect that Orthofix International N.V. will post $1.55 EPS for the current fiscal year.
A number of analysts have weighed in on the company. BidaskClub lowered Orthofix International N.V. from a buy rating to a hold rating in a report on Tuesday, August 1st. Zacks Investment Research upgraded Orthofix International N.V. from a sell rating to a hold rating in a report on Thursday, July 6th. BTIG Research assumed coverage on Orthofix International N.V. in a report on Wednesday, June 21st. They set a buy rating and a $52.00 target price for the company. Langenberg & Company restated a buy rating and set a $53.25 target price on shares of Orthofix International N.V. in a report on Wednesday, June 14th. Finally, Ladenburg Thalmann Financial Services assumed coverage on Orthofix International N.V. in a report on Wednesday, June 14th. They set a buy rating and a $53.25 target price for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Orthofix International N.V. currently has an average rating of Buy and an average price target of $51.88.
About Orthofix International N.V.
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.